ppt of eicosanoids and paf
DESCRIPTION
By ramu sankulaTRANSCRIPT
![Page 1: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/1.jpg)
S.RAMU13H61S0108M.PHARMACYDEPT OF PHARMACOLOGY
![Page 2: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/2.jpg)
Overview
Eicosanoids are a large group of autocoids with potent effects on virtually every tissue in the body
these agents are derived from metabolism of 20-carbon, unsaturated fatty acids (eicosanoic acids).
![Page 3: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/3.jpg)
.
The eicosanoids include:
1. the prostaglandins
2. thromboxanes
3. leukotrienes
4. hydroperoxyeicosatetraenoic acids (HPETEs)
5. hydroxyeicosatetraenoic acids (HETEs).
![Page 4: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/4.jpg)
Biosynthesis
Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:.
![Page 5: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/5.jpg)
Biosynthesis
Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:
1. Phospholipase A2-mediated production from membrane phospholipids; this pathway is inhibited by glucocorticoids.
![Page 6: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/6.jpg)
Biosynthesis
Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:
1. Phospholipase A2-mediated production from membrane phospholipids; this pathway is inhibited by glucocorticoids.
2. Phospholipase C.
![Page 7: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/7.jpg)
![Page 8: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/8.jpg)
![Page 9: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/9.jpg)
Eicosanoids are synthesized by two pathways:
1. The prostaglandin H synthase (COX, cyclooxygenase) pathway
produces: A. thromboxane B. the primary prostaglandins
prostaglandin E, or PGE prostaglandin F, or PGF prostaglandin D, or PGD)
C. prostacyclin (PGI2)
![Page 10: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/10.jpg)
.2. The lipoxygenase pathway produces:
HPETEs HETEs leukotrienes
![Page 11: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/11.jpg)
RECEPTORSPROSTAGLANDINS
PGE - EP1, EP2, EP3, EP4.
PGF - FP
PGD - DP
THROMBOXANE - TP
PROSTACYCLINS
PGI - IP
LEUKOTRIENES - LT1, LT2, LT3, LT4.
![Page 12: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/12.jpg)
Actions:Vascular smooth muscle
○ PGE2 and PGI2 are potent vasodilators in most vascular beds.
○ Thromboxane is a potent vasoconstrictor.
![Page 13: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/13.jpg)
.Inflammation
○PGE2 and PGI2 cause an increase in blood flow and promote, but do not cause, edema.
○HETEs (5-HETE, 12-HETE, 15-HETE) and leukotrienes cause chemotaxis of neutrophils and eosinophils.
![Page 14: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/14.jpg)
. Bronchial smooth muscle PGFs cause smooth muscle
contraction.○PGEs cause smooth muscle
relaxation.
![Page 15: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/15.jpg)
. Bronchial smooth muscle PGFs cause smooth muscle
contraction.○PGEs cause smooth muscle
relaxation.○Leukotrienes and thromboxane
are potent bronchoconstrictors and are the most likely candidates for mediating allergic bronchospasm.
![Page 16: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/16.jpg)
. Uterine smooth muscle. PGE2 and PGF2a
cause contraction of uterine smooth muscle in pregnant women.
![Page 17: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/17.jpg)
. Uterine smooth muscle. PGE2 and PGF2a
cause contraction of uterine smooth muscle in pregnant women.
The nonpregnant uterusnonpregnant uterus has a more variable response to prostaglandins PGF2a causes contraction
PGE2 causes relaxation.
![Page 18: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/18.jpg)
Gastrointestinal tract ○ PGE2 and PGF2a
- increase the rate of longitudinal contraction in the gut and decrease transit time.
○ The leukotrienes - are potent stimulators of gastrointestinal
smooth muscle.
○ PGE2 and PGI2
- inhibit acid and pepsinogen secretion in the stomach.
![Page 19: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/19.jpg)
Blood ○ TXA2
- is a potent inducer of platelet aggregation.○ PGI2 and PGE2
- inhibit platelet aggregation.○ PGEs
- induce erythropoiesis by stimulating the renal release of erythropoietin.
○ 5-HPETE - stimulates release of histamine
○ PGI2 and PGD - inhibit histamine release.
![Page 20: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/20.jpg)
Therapeutic uses Induction of labor at term. Induction of labor is produced by:
infusion of PGF2 (carboprost tromethamine) [Hemabate] or
PGE2 (dinoprostone) [Prostin E].
![Page 21: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/21.jpg)
Therapeutic abortion:
A.Inducing abortion in the second trimester: Infusion of carboprost tromethamine or Administration of vaginal suppositories
containing dinoprostone
B.inducing first-trimester abortion:○ these prostaglandins are combined with
mifepristone (RU486)
![Page 22: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/22.jpg)
[[Maintenance of ductus
arteriosus
is produced by PGE1 [Prostin VR] infusion
PGE1 will maintain patency of the ductus arteriosus, which may be desirable before surgery.
![Page 23: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/23.jpg)
Treatment of peptic ulcer.
Misoprostol [Cytotec] ○ a methylated derivative of PGE1
○ is approved for use in patients taking high doses of nonsteroidal antiinflammatory drugs (NSAIDs) to reduce gastric ulceration.
![Page 24: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/24.jpg)
Treatment of Glaucoma
Latanoprost - 0.3% solution (Xalatan) Trovoprost (Travatan) Tefluprost (Zioptan)
Bimatoprost (Lumigan)
![Page 25: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/25.jpg)
Adverse effects local pain and irritation bronchospasm gastrointestinal disturbances: nausea,
vomiting, cramping, and diarrhea.
![Page 26: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/26.jpg)
MONTEUKAST
ZAFIRLEUKAST
PRANLEUKAST
ZILEUTON
NSAIDS
CORTICOSTEROIDS
![Page 27: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/27.jpg)
MONTEUKAST
ZAFIRLEUKAST
PRANLEUKAST
ZILEUTON
NSAIDS
CORTICOSTEROIDS
![Page 28: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/28.jpg)
PLATELET ACTIVATINGFACTOR
![Page 29: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/29.jpg)
PAF also termed PAF- acether and AGEPC ( acetyl- glyceyl-ether-phosphorylcholine)
Biologically active phospholipid
![Page 30: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/30.jpg)
BIOSYNTHESIS
Synthesized from acyl-PAF by two step process and under goes ACETYLATION DEACETYLATION
![Page 31: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/31.jpg)
Phospholipid Arachidonic acid
acyl Co A Lys-PAF(INACTIVE)
PLA 2
acetyl hydrolase
PAF (ACTIVE) Lys-PAF (INACTIVE)
acetyl transferase
![Page 32: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/32.jpg)
ACTIONS Vasodilatation Increased vascular permeability Chemotaxis Activation of leukocytes Aggregation of platelets Smooth muscle contraction
![Page 33: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/33.jpg)
ANTAGONISTS
Rupatidine Lexipafant CV-3988 SM-12502 WEB-2086
![Page 34: PPT of Eicosanoids and PAF](https://reader036.vdocument.in/reader036/viewer/2022081422/554b004cb4c90559058b5300/html5/thumbnails/34.jpg)